Hummingbird Bioscience Entered into a Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate HMBD-001 for Squamous Non-Small Cell Lung Carcinoma
Shots:
- The company collaborated to evaluate HMBD-001 (HER3-targeting Ab) in combination with cetuximab in a P-Ib trial for sq. NSCLC. The trial is expected to initiate in H2’23
- The companies’ focus is to evaluate the safety, tolerability & anti-tumor activity of HMBD-001 + CT with/out cetuximab. Merck will supply cetuximab for the Hummingbird Bioscience-sponsored study while both companies will retain all commercial rights to their respective compounds
- HMBD-001 inhibits tumor growth more effectively & with higher affinity over other anti-HER3 Abs in preclinical models. The therapy has been developed using Hummingbird's rational antibody discovery platform & is currently in development for multiple solid tumors
Ref: PR Newswire | Image: Hummingbird
Related News:- Hummingbird Collaborates with Novogene to Expand Precision Therapy Testing for NRG1-Fusion Driven Cancers in China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
